Consequences of menopause in women with diabetes mellitus – a clinical problem

References

• Milewicz A, Tworowska U, Demissie M. Menopausal obesity–myth of fact?. Climacteric 2001; 4: 273–283
   PubMedGoogle Scholar
• Lamberts S W, van den Belt A W, van der Ley A J. The endocrinology of aging. Science 1997; 278: 419–424
   PubMed Web of Science ®Google Scholar
• Milewicz A, Jedrzejuk D, Bohdanowicz-Pawlak A, Medras M. Metabolic and hormonal changes after DHEA treatment. The 9th International Menopause Society world congress on the menopause, Yokohama (Japan), T Aso, T Yanaihara, Y Taketani, T Suda. Monduzzi, Bologna 1999; 215–220
   Google Scholar
• Milewicz A, Zatonska K, Demissie M, Jedrzejuk D, Dunajska K, Ilow R, Lwow F. Serum adiponectin concentration and cardiovascular risk factors in climacteric women. Gynecol Endocrinol 2002; 20: 68–73
   Google Scholar
• Milewicz A, Demissie M. Metabolic and endocrine changes in climacteric women. Midlife health–current concepts and challenges for the future, G Samsioe, S Skouby. Excerpta Medica/Elsevier Science BV, Amsterdam 2002; 3–7, (International congress series; 1229).
   Google Scholar
• Freedland E S. Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutr Metab 2004; 12: 1–24
   Google Scholar
• Wajchenberg B L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697–738
   PubMed Web of Science ®Google Scholar
• Deng H W, Li J, Li J L, Dowd R, Davies K M, Johnson M, Gong G, Deng H, Recker R R. Association of estrogen receptor-α genotypes with body mass index in normal healthy postmenopausal Caucasian women. J Clin Endocrinol Metab 2000; 85: 2748–2751
   PubMed Web of Science ®Google Scholar
• Bottini N, MacMurray J, Peters W, Rostamkhani M, Comings D E. Association of the acid phosphatase (ACP1) gene with triglyceride levels in obese women. Mol Genet Metab 2002; 77: 226–229
   PubMedGoogle Scholar
• Paterson J M, Morton N M, Fievet C, Kenyon C J, Holmes M C, Staels B, Seckl J R, Mullins J J. Metabolic syndrome without obesity; hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A 2004; 101: 7088–7093
   PubMed Web of Science ®Google Scholar
• Milewicz A, Bidzinska B, Mikulski E, Demissie M, Tworowska U. Influence of obesity and menopausal status on serum leptin, cholecystokinin, galanin and neuropeptide Y levels. Gynecol Endocrinol 2000; 14: 196–200
   PubMed Web of Science ®Google Scholar
• Sclavo M. Cardiovascular risk factors and prevention in women: similarities and differences. Ital Heart J 2001; 2(2 Suppl)125–141
   Google Scholar
• Dobs A S, Nguyen T, Pace C, Roberts C P. Differential effects of oral estrogen versus oral estrogen – androgen replacement therapy on body composition in postmenopausal women. J Clin Endocrinol Metab 2002; 87: 1509–1516
   PubMed Web of Science ®Google Scholar
• The IDF consensus worldwide definition of the metabolic syndrome. Berlin 14th April, 2005, Available: http://www.idf.org
   Google Scholar
• Khoo C L, Perera M. Diabetes and the menopause. J Br Menopause Soc 2005; 11: 6–11
   PubMedGoogle Scholar
• Effects of menopause and estrogen replacement therapy or hormone replacement therapy in women with diabetes mellitus: consensus opinion of the North American Menopause Society. Menopause 2000; 7: 87–95
   PubMed Web of Science ®Google Scholar
• Kalish G M, Barrett-Connor E, Laughlin G A, Gulanski B I. Postmenopausal Estrogen/Progestin Intervention Trial. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention trial. J Clin Endocrinol Metab 2003; 88: 1646–1652
   PubMed Web of Science ®Google Scholar
• Conus F, Allison D B, Rabasa-Lhoret R, St-Onge M, St-Pierre D H, Tremblay-Lebeau A, Poehlman E T. Metabolic and behavioral characteristics of metabolically obese but normal-weight women. J Clin Endocrinol Metab 2004; 89: 5013–5020
   PubMed Web of Science ®Google Scholar
• Hrebicek J, Janout V, Malincikova J, Horakova D, Cizek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab 2002; 87: 144–147
   PubMed Web of Science ®Google Scholar
• Fisman E Z, Tenenbaum A, Pines A. Systematic hypertension in postmenopausal women: a clinical approach. Curr Hypertens Rep 2002; 4: 464–470
   PubMedGoogle Scholar
• Pines A. Alternations in cardiac hemodynamics associated with menopause and HRT. >Menopause and the heart, M Neves-e-Castro, M Birkauser, T B Clarkson, P Collins. Parthenon Publishing, New York 1999; 35–39
   Google Scholar
• Kaseta J R, Skafar D F, Ram J L, Jacober S J, Sowers J R. Cardiovascular disease in diabetic women. J Clin Endocrinol Metab 1999; 84: 1835–1838
   PubMed Web of Science ®Google Scholar
• McFarlane S I, Banerji M L, Sowers J R. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713–718
   PubMed Web of Science ®Google Scholar
• Mogul H R, Weinstein B I, Mogul D B, Peterson S J, Zhang S, Frey M, Gambert S R, Southren A L, Syndrome W. a new model of hyperinsulinemia, hypertension and midlife gain in healthy woman with normal glucose tolerance. Heart Dis 2002; 4: 78–85
   PubMedGoogle Scholar
• Marceau P, Biron S, Hould F S, Marceau S, Simard S, Thung S N, Kral J G. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513–1517
   PubMed Web of Science ®Google Scholar
• Deng H W, Li J, Li J L, Dowd R, Davies K M, Johnson M, Gong G, Deng H, Recker R R. Association of estrogen receptor α genotypes with body mass index in normal healthy postmenopausal Caucasian women. J Clin Endocrinol Metab 2000; 85: 2748–2751
   PubMed Web of Science ®Google Scholar
• Reaven G M, Brand R J, Chen Y D, Mathur A K, Goldfine I. Insulin resistance and insulin secretion are determinants of oral glucose tolerance in normal individuals. Diabetes 1993; 42: 1324–1332
   PubMedGoogle Scholar
• Milewicz A. Obesity phenotypes, body mass composition and metabolic profile. Endocrinol Obes Metab Disord 2005; 1: 15–20
   Google Scholar
• Zdrojewski T. Ocena wybranych problemów dotyczących rozpowszechnienia i terapii nadciśnienia tętniczego w Polsce na podstawie badania NATPOL-PLUS [Selected problems associated with epidemiology and therapy of hypertension in Poland on the basis of NATPOL-PLUS study]. Medycyna Praktyczna 2002; 1–15
   Google Scholar
• Executive summary of the third report of the National Cholesterol Education Program (CEP) Export Panel on Detection, Evaluation and Treatment of High Blond Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486–2497
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Natali A. Essential hypertension, metabolic disorders and insulin resistance. Am Heart J 1991; 121: 1274–1282
   PubMed Web of Science ®Google Scholar
• Nadel I, Cypryk K, Pertynski T, Sobczuk A, Stetkiewicz T. Studies on the incidence and clinical significance of the metabolic syndrome in postmenopausal women in Lodz region. Pol Arch Med Wewn 2001; 106: 823–828
   PubMedGoogle Scholar
• Milewicz A, Jedrzejuk D, Lwow F, Bialynicka A S, Lopatynski J, Mardarowicz G, Zahorska-Markiewicz B. Prevalence obesity in Poland. Obes Res 2005; 6: 113–114
   Google Scholar
• Mahler R J, Adler M L. Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab 1999; 84: 1165–1171
   PubMed Web of Science ®Google Scholar
• Perera M, Petrie J R, Hillier C, Small M, Sattar N, Connell J M, Lumsden M A. Hormone replacement therapy can augment vascular relaxation in postmenopausal women with type 2 diabetes. Hum Reprod 2002; 17: 497–502
   PubMedGoogle Scholar
• Kanaya A M, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley J A, Barrett-Connor E. Heart and Estrogen/progestin Replacement Study. Glycemic effects of postmenopausal hormonal therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138: 1–9
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, LaCroix A Z, Kooperberg C, Stefanick M L, Jackson R D, Beresford S A, Howard B V, Johnson K C, et al. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen and progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321–323
   PubMed Web of Science ®Google Scholar
• Ferrara A, Quesenberry C P, Karter A J, Njoroge C W, Jacobson A S, Selby J V. Northern California Kaiser Permanente Diabetes Registry. Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry 1995–1998. Circulation 2003; 107: 43–48
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Pringle M, Crown N, Coupland C. A case – control study on the effect of hormone replacement therapy on ischaemic heart disease. Br J Gen Pract 2003; 53: 191–196
   PubMedGoogle Scholar
• Hayward C S, Samaras K, Campbell L, Kelly R P. Effect of combination hormone replacement therapy on ambulatory blood pressure and arterial stiffness in diabetic postmenopausal women. Am J Hypertens 2001; 14: 699–703
   PubMed Web of Science ®Google Scholar
• Ferrara A, Karter A J, Ackerson L M, Liu J Y, Selby J V, Northern California Kaiser Permanente Diabetes Registry. Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes. The Northern California Kaiser Permanente Diabetes Registry. Diabetes Care 2001; 24: 1144–1150
   PubMed Web of Science ®Google Scholar
• Crespo C J, Smit E, Snelling A, Sempos C T, Andersen R E, NHANES III. Hormone replacement therapy and its relationship to lipid and glucose metabolism in diabetic and nondiabetic postmenopausal women: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2002; 25: 1675–1680
   PubMed Web of Science ®Google Scholar
• Godsland I F, Gangar K, Walton C, Cust M P, Whitehead M I, Wynn V, Stevenson J C. Insulin resistance, secretion, and elimination in the post menopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993; 42: 846–853
   PubMed Web of Science ®Google Scholar
• Luotola H, Pyorala T, Loikkanen M. Effects of natural estrogen/progestagen substitution therapy on carbohydrate and lipid metabolism in postmenopausal women. Maturitas 1986; 8: 245–253
   PubMedGoogle Scholar
• Crook D, Godsland I F, Hull J, Stevenson J C. Hormone replacement therapy with dydrogesterone and 17-β estradiol: effects on serum lipoproteins and glucose tolerance during 24 months follow up. Br J Obstet Gynaecol 1997; 104: 298–304
   PubMedGoogle Scholar
• Zhang Y, Howard B V, Cowan L D, Welty T K, Schaefer C F, Wild R A, Yeh J, Lee E T. Associations of postmenopausal hormone therapy with markers of homeostasis and inflammation and lipid profiles in diabetic and nondiabetic Indian women: the strong heart study. J Womens Health (Larchmt) 2004; 13: 155–163
   PubMedGoogle Scholar
• Skouby S O, Al-Azzawi F, Barlow D, Calaf-Alsina J Erdogan Ertungealp, Gompel A, Graziottin A, Hudita D, Pines A, Rozenberg S, Samsioe G, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 2005; 51: 8–14
   PubMed Web of Science ®Google Scholar
• Pines A, Bornstein N M, Shapira I. Menopause and ischemic stroke: basic, clinical and epidemiological considerations. The role of hormone replacement. Hum Reprod Update 2002; 8: 161–168
   PubMedGoogle Scholar
• Al-Delaimy W K, Willett W C, Manson J E, Speizer F E, Hu F B. Smoking and mortality among women with type 2 diabetes: the Nurses' Health Study cohort. Diabetes Care 2001; 24: 2043–2048
   PubMed Web of Science ®Google Scholar
• Rodriguez C, Calle E E, Patel A V, Tatham L M, Jacobs E J, Thun M J. Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women. Am J Epidemiol 2002; 153: 145–152
   Google Scholar
• Nicodemus K K, Folsm A R. Iowa Women's Health Study: type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001; 24: 1192–1197
   PubMed Web of Science ®Google Scholar
• Akin O, Gol K, Akturk M, Erkaya S. Evaluation of bone turnover in postmenopausal women with type 2 diabetes mellitus using biochemical markers and bone density measurements. Gynecol Endocrinol 2003; 17: 19–29
   PubMed Web of Science ®Google Scholar
• Isaia G C, Ardissone P, Di Stefano M, Ferrari D, Martina V, Porta M, Tagliabue M, Molinatti G M. Bone metabolism in type 2 diabetes mellitus. Acta Diabetol 1999; 36: 35–38
   PubMed Web of Science ®Google Scholar
• Stevenson J C. Justification for the use of HRT in the long-term prevention of osteoporosis. Maturitas 2005; 51: 113–126
   PubMed Web of Science ®Google Scholar
• Guastamacchia E, Resta F, Mangia A, Schittulli F, Ciampolillo A, Triggiani V, Licchelli B, Paradiso A, Sabba C, Tafaro E. Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3: 205–209
   PubMedGoogle Scholar
• Zendehdel K, Nyren O, Ostenson C G, Adami H O, Ekbom A, Ye W. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 2003; 95: 1797–1800
   PubMed Web of Science ®Google Scholar
• Folsom A R, Anderson K E, Sweeney C, Jacobs D R, Jr. Diabetes as a risk factor for death following endometrial cancer. Gynecol Oncol 2004; 94: 740–745
   PubMed Web of Science ®Google Scholar
• Svacina S, Matoulek M, Svobodova S, Visokai V, Lipska L, Topolcan O, Zvarova J, Plavcova M. Gastrointestinal tract cancer and diabetes mellitus. Vnitr Lek 2004; 50: 386–391
   PubMedGoogle Scholar
• Hu F B, Manson J E, Liu S, Hunter D, Colditz G A, Michels K B, Speizer F E, Giovannucci E. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999; 91: 542–547
   PubMed Web of Science ®Google Scholar
• Dal Maso L, Augustin L S, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros C S, La Vecchia C. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004; 89: 1160–1163
   PubMed Web of Science ®Google Scholar
• Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe D M, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004; 89: 1102–1107
   PubMed Web of Science ®Google Scholar
• Prisant L M. Preventing type 2 diabetes mellitus. J Clin Pharmacol 2004; 44: 406–413
   PubMed Web of Science ®Google Scholar
• Abraham W T. Preventing cardiovascular events in patients with diabetes mellitus. Am J Med 2004; 8(Suppl 5A)39S–46S
   Google Scholar
• Milewicz A, Szymanski W, Ruzyllo W, Zgliczynski S, Reinfus M, Zielinski J, Debski R, Demissie M, Tworowska U. Polish consensus: procedure in case of estrogen deficiency in women after breast cancer therapy. Gynecol Endocrinol 2002; 16: 385–389
   PubMedGoogle Scholar
• Milewicz A, Jedrzejuk D, Lwow F. Prevention and alternative treatment to HRT in women after breast cancer surgery. Terapia 2002; 6: 19–23
   Google Scholar
• Shanafelt T D, Barton D L, Adjei A A, Loprinzi C L. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002; 77: 1207–1218
   PubMed Web of Science ®Google Scholar
• Keegan T H, Schwartz A V, Bauer D C, Sellmeyer D E, Kelsey J L. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care 2004; 27: 1547–1553, The fracture intervention trial
   PubMed Web of Science ®Google Scholar
• Maugeri D, Panebianco P, Rosso D, Calanna A, Speciale S, Santangelo A, Rizza I, Motta M, Lentini A, Malaguarnera M. Alendronate reduces the daily consumption of insulin (DCI) in patients with senile type 1 diabetes and osteoporosis. Arch Gerontol Geriatr 2002; 34: 117–122
   PubMedGoogle Scholar
• Panagiotakos D B, Polychronopulos E. The role of Mediterranean diet in the epidemiology of metabolic syndrome; converting epidemiology to clinical practice. Lipids Health Dis 2005; 4: 7
   PubMedGoogle Scholar